Thiogenesis Therapeutics, Corp. TTI.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -29.41% | -82.50% | -132.74% | -62.68% | -9.99% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.74% | 94.95% | 119.74% | 183.33% | 59.40% |
| Change in Net Operating Assets | -172.46% | -61.50% | 151.85% | 568.75% | 1,322.09% |
| Cash from Operations | -100.78% | -116.00% | -50.52% | -11.46% | 22.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,572.40% | 1,360.94% | 426.90% | -11.44% | -94.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,629.65% | 1,383.86% | 422.64% | -12.69% | -94.47% |
| Foreign Exchange rate Adjustments | -165.88% | 12.61% | 64.91% | -1,530.43% | 45.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 275.33% | 15.98% | 33.61% | -217.28% | -1,110.54% |